Make pancreatic cancer a treatable condition through applying next-gen diagnostics and therapeutics, identified through cutting-edge omics, bioinformatics and systems-level strategies.
Pancreatic Cancer is a devastating disease that is projected to be the 2nd leading cancer killer by 2020.
Pancreatic Cancer is one of the most lethal cancers, primarily due to the vast majority of cases being diagnosed at an advanced, incurable stage.We view this as unacceptable.
While overall 5-year survival of metastatic pancreatic cancer is <5%, outcomes dramatically improve for localized pancreatic cancer.
Poor prognosis is mainly due to a lack of biomarkers for diagnosing pancreatic cancer at an early, asymptomatic stage when cure is possible.
Effective screening for early stage pancreatic cancer depends on identification of accurate, non-invasive biomarkers in combination with a strategy for screening increased-risk populations.
Since development of metastatic pancreatic cancer from its precursor lesions may take up to 20 years, there is a large window of opportunity for earlier detection.
Earlier Diagnostic => More Efficacious Therapy
Using cutting edge omics technologies biomaRx has identified non-invasive biomarkers that accurately detect pancreatic cancer before it becomes invasive and distinguish between patients with and without advanced pancreatic cancer.
biomaRx is developing robust liquid biopsy diagnostics to assess the risk of malignant potential of PDAC precursor lesions and screening approaches for early detection of PDAC in increased-risk subjects.
Our diagnostic test will shift the detection of pancreatic cancer to an earlier stage when therapeutic intervention is a viable option.
Developed at Harvard Medical School, biomaRx has applied a disruptive, proprietary systems biology engine to identify and deliver first-in-class therapeutics for high priority drug targets in pancreatic cancer.
We are validating a promising liquid biopsy diagnostic and combo therapeutic, with pivotal studies underway.